Palisade Bio
PALI
8 hedge funds and large institutions have $489K invested in Palisade Bio in 2020 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.
60% more funds holding
Funds holding: 5 → 8 (+3)
36% more capital invested
Capital invested by funds: $359K → $489K (+$130K)
0% less ownership
Funds ownership: 0% → 0% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$57.8K |
| 2 |
HF
HRT Financial
New York
|
+$10.8K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$10.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$7.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$1K |
PALI Hedge Fund Activity: Q2 2020 in Review
8 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q2 2020, worth a combined $489K — up 36% from $359K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new PALI positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $57.8K. The largest seller was Victory Capital Management, cutting an estimated $1K.
- 8 institutional investors held Palisade Bio (PALI) as of Q2 2020, up from 5 in Q1 2020.
- Funds reported $489K of Palisade Bio stock for Q2 2020, up 36% quarter-over-quarter.
- 3 funds opened new Palisade Bio positions in Q2 2020 and 0 closed out, a net change of +3 holders.
- The largest Palisade Bio buyer in Q2 2020 was Renaissance Technologies, an estimated $57.8K added.
- The largest Palisade Bio seller in Q2 2020 was Victory Capital Management, an estimated $1K sold.
Based on aggregated 13F filings for Q2 2020.